HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Colorectal liver metastatic disease: efficacy of irreversible electroporation--a single-arm phase II clinical trial (COLDFIRE-2 trial).

AbstractBACKGROUND:
Irreversible electroporation (IRE) is a novel image-guided tumor ablation technique that has shown promise for the ablation of lesions in proximity to vital structures such as blood vessels and bile ducts. The primary aim of the COLDFIRE-2 trial is to investigate the efficacy of IRE for unresectable, centrally located colorectal liver metastases (CRLM). Secondary outcomes are safety, technical success, and the accuracy of contrast-enhanced (ce)CT and (18)F-FDG PET-CT in the detection of local tumor progression (LTP).
METHODS/DESIGN:
In this single-arm, multicenter phase II clinical trial, twenty-nine patients with (18)F-FDG PET-avid CRLM ≤ 3,5 cm will be prospectively included to undergo IRE of the respective lesion. All lesions must be unresectable and unsuitable for thermal ablation due to vicinity of vital structures. Technical success is based on ceMRI one day post-IRE. All complications related to the IRE procedure are registered. Follow-up consists of (18)F-FDG PET-CT and 4-phase liver CT at 3-monthly intervals during the first year of follow-up. Treatment efficacy is defined as the percentage of tumors successfully eradicated 12 months after the initial IRE procedure based on clinical follow-up using both imaging modalities, tumor marker and (if available) histopathology. To determine the accuracy of (18)F-FDG PET-CT and ceCT, both imaging modalities will be individually scored by two reviewers that are blinded for the final oncologic outcome.
DISCUSSION:
To date, patients with a central CRLM unsuitable for resection or thermal ablation have no curative treatment option and are given palliative chemotherapy. For these patients, IRE may prove a life-saving treatment option. The results of the proposed trial may represent an important step towards the implementation of IRE for central liver tumors in the clinical setting.
TRIAL REGISTRATION:
TRIAL REGISTRATION NUMBER:
NCT02082782.
AuthorsHester J Scheffer, Laurien G P H Vroomen, Karin Nielsen, Aukje A J M van Tilborg, Emile F I Comans, Cornelis van Kuijk, Bram B van der Meijs, Janneke van den Bergh, Petrousjka M P van den Tol, Martijn R Meijerink
JournalBMC cancer (BMC Cancer) Vol. 15 Pg. 772 (Oct 24 2015) ISSN: 1471-2407 [Electronic] England
PMID26497813 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
Chemical References
  • Fluorodeoxyglucose F18
Topics
  • Ablation Techniques (methods)
  • Aged
  • Colorectal Neoplasms (pathology)
  • Electroporation
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Liver Neoplasms (secondary, surgery)
  • Male
  • Middle Aged
  • Survival Analysis
  • Tomography, X-Ray Computed (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: